Isaac Barchas Sells 20,840 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 20,840 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $26.06, for a total transaction of $543,090.40. Following the completion of the transaction, the director owned 87,664 shares in the company, valued at approximately $2,284,523.84. This trade represents a 19.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total transaction of $397,362.88.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The stock was sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $26.25 on Wednesday. Immunome, Inc. has a 52-week low of $8.66 and a 52-week high of $27.65. The firm has a fifty day moving average of $21.73 and a 200 day moving average of $22.18. The firm has a market capitalization of $2.97 billion, a PE ratio of -11.03 and a beta of 2.08.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, sell-side analysts forecast that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Analysts Set New Price Targets

IMNM has been the subject of a number of recent research reports. Citigroup restated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Leerink Partners decreased their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Finally, Truist Financial upped their price objective on shares of Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $34.18.

Institutional Trading of Immunome

Institutional investors have recently made changes to their positions in the stock. Allworth Financial LP purchased a new position in shares of Immunome in the second quarter worth $25,000. E Fund Management Co. Ltd. purchased a new stake in Immunome during the 2nd quarter valued at $248,000. Citizens Financial Group Inc. RI purchased a new stake in Immunome during the 2nd quarter valued at $424,000. BlackRock Inc. bought a new stake in Immunome in the 2nd quarter worth $186,588,000. Finally, Deutsche Bank AG bought a new stake in Immunome in the 2nd quarter worth $2,365,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.